References
- Cooper DS. Antithyroid drugs. N Engl J Med 352, 905–917, 2005.
- Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. European Thyroid Association Guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J 7, 167–186, 2018.
- Kamitani F, Nishioka Y, Koizumi M, Nakajima H, Kurematsu Y, Okada S, Kubo S, Myojin T, Noda T, Imamura T, Takahashi Y. Antithyroid drug-induced leukopenia and G-CSF administration: a long-term cohort study. Sci Rep 13, 19336, 2023.
- Liu Y, Li Q, Xu Y, Chen Y, Men Y. Comparison of the safety between propylthiouracil and methimazole with hyperthyroidism in pregnancy: A systematic review and meta-analysis. PLoS One 18, e0286097, 2023.
- Noh JY, Inoue K, Suzuki N, Yoshihara A, Fukushita M, Matsumoto M, Imai H, Hiruma S, Ichikawa M, Koshibu M, Sankoda A, Hirose R, Watanabe N, Sugino K, Ito K. Dose-dependent incidence of agranulocytosis in patients treated with methimazole and propylthiouracil. Endocr J 71, 695–703, 2024.
- Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug–induced agranulocytosis: the usefulness of routine white blood cell count monitoring. Arch Intern Med 150, 621–624, 1990.
- Vicente N, Cardoso L, Barros L, Carrilho F. Antithyroid drug-induced agranulocytosis: state of the art on diagnosis and management. Drugs R D 17, 91–96, 2017.